Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602822 · ClinicalTrials.gov registry record · Phase 4
Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV
A Phase 4 study, sponsored by Kenneth H. Mayer, MD.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT01602822: Clinical Trial Phase 4 study, sponsored by Kenneth H. Mayer, MD.
NCT01602822 is a Phase 4 study that was terminated before completion, run by Kenneth H. Mayer, MD. The registered enrollment target is 11 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01602822, a Phase 4 study, was terminated before completion, sponsored by Kenneth H. Mayer, MD.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
Primary Outcome
Number of subjects who experienced moderate-to-severe symptoms on the symptom-directed physical exam at or before visit 3.
Interventions
- DRUG Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2012-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 4 |
Why NCT01602822 stopped before completion
NCT01602822 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir is the first listed.
NCT01602822 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01602822 about?
NCT01602822 is a clinical study titled "Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV". This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
What is the current status of trial NCT01602822?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2012-02. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01602822?
The interventions under investigation include: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir (DRUG).
Who is sponsoring clinical trial NCT01602822?
This trial is sponsored by Kenneth H. Mayer, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01602822's enrollment target sits among peer trials
11 1931st of 2000 higher than 61 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia